2015
DOI: 10.1007/s10637-015-0272-0
| |Summarize |Cite
|
Sign up to set email alerts

Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer

Abstract: SummaryBackground Modufolin® ([6R]-5,10-methylene tetrahydrofolate; [6R]-MTHF) is an endogenous biomodulator that is being developed as an alternative to leucovorin, a folate prodrug used in the treatment of colorectal cancer. The objective of this phase 1 dose de-escalation trial was to estimate the minimum tolerated dose of [6R]-MTHF to be used in combination with pemetrexed 500 mg/m2 in the neoadjuvant treatment of patients with rectal cancer. Methods Adult patients (≥18 years) with resectable rectal adenoc… Show more

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
0
0

Citation Types

0
1
0
0

Year Published

Range
2018
2018
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 46 publications

0
1
0
0
Order By: Relevance
How the paper below cites the one you are viewing
“…There are also different analogs for MTT in various stages of preclinical and clinical development [ 7 , 8 ]. Pemetrexed, a potent polyglutamate classic antifolate TS inhibitor formerly called LY23154 [ 9 ], is an interesting new antifolate.…”
Section: Introduction
mentioning
confidence: 99%